INCLUSION CRITERIA:

          -  Diagnostic criteria: Patients must have one of the following diagnoses:

               -  Acute myeloid leukemia fulfilling the criteria of the WHO Classification (see
                  Appendix I), or

               -  >5% but < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic
                  abnormality [e.g., t(8;21), inv(16), t(9;11)], or

               -  Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic
                  sarcoma, or chloroma), with or without evidence of a leukemia process in the bone
                  marrow or peripheral blood, with confirmation of myeloid differentiation, or

               -  High grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or

               -  Patients with treatment related myeloid neoplasms including AML and MDS, provided
                  their cumulative anthracycline dose has not exceeded 230 mg/m2 doxorubicin
                  equivalents.

          -  Other criteria - Patients must meet all the following criteria:

               -  Age > 28 days and < 22 years at time of study entry inclusive, and

               -  No prior therapy for this malignancy except for one dose of intrathecal therapy
                  and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one
                  week or less for hyperleukocytosis), and

               -  Written informed consent according to institutional guidelines, and

               -  Female patients of childbearing potential must have a negative pregnancy test
                  within 2 weeks prior to enrollment, and

               -  Male and female participants of reproductive potential must use an effective
                  contraceptive method during the study and for a minimum of 6 months after study
                  treatment.

        EXCLUSION CRITERIA:

          -  Down syndrome

          -  Acute promyelocytic leukemia (APL)

          -  BCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)

          -  Juvenile myelomonocytic leukemia (JMML)

          -  Fanconi anemia (FA)

          -  Kostmann syndrome

          -  Shwachman syndrome

          -  Other bone marrow failure syndromes or low grade (<5% bone marrow blasts) MDS.

          -  Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as
             specified in the protocol.

          -  Use of investigational agents within 30 days or any anticancer therapy for this
             malignancy within 2 weeks before study entry with the exception of IT therapy,
             hydroxyurea, or low-dose cytarabine as specified in the protocol document. The patient
             must have recovered from all acute toxicities from any previous therapy.

          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment).

          -  Pregnant or lactating.

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, interfere with consent, study participation,
             follow up, or interpretation of study results.

          -  Prior chemotherapy, with the exception of hydroxyurea or low-dose cytarabine as
             specified in the protocol document. The patient must have recovered from all acute
             toxicities from any previous therapy.

          -  Patients with treatment related myeloid neoplasms with cumulative anthracyclines
             greater than 230 mg/m2 doxorubicin equivalents.